Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,018 | 9,364 | 11,050 | 13,130 | 15,310 |
| Other current assets | 0 | 0 | 90 | 80 | 110 |
| TOTAL | $7,155 | $9,517 | $11,140 | $13,210 | $15,420 |
| Non-Current Assets | |||||
| PPE Net | 7 | 8 | N/A | N/A | N/A |
| Intangibles | 28 | 30 | 0 | 0 | 0 |
| Other Non-Current Assets | 6 | 6 | 36 | 90 | 90 |
| TOTAL | $41 | $44 | $36 | $90 | $90 |
| Total Assets | $7,196 | $9,561 | $11,190 | $13,320 | $15,530 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 316 | 397 | 250 | 240 | 660 |
| Accrued Expenses | 1,152 | 1,161 | 1,180 | 1,330 | 1,260 |
| Other current liabilities | N/A | N/A | 0 | 200 | 200 |
| TOTAL | $1,468 | $1,638 | $1,440 | $1,780 | $2,130 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5 | 6 | 0 | 0 | 0 |
| TOTAL | $5 | $6 | $N/A | $N/A | $N/A |
| Total Liabilities | $1,473 | $1,644 | $1,440 | $1,780 | $2,130 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 16,251 | N/A | N/A | N/A | N/A |
| Common Shares | 16 | 16 | 10 | 10 | 10 |
| Retained earnings | -83,490 | -80,018 | -77,310 | -74,320 | -71,340 |
| Other shareholders' equity | 7,391 | 7,384 | 7,340 | 7,270 | 7,220 |
| TOTAL | $5,723 | $7,917 | $9,750 | $11,540 | $13,400 |
| Total Liabilities And Equity | $7,196 | $9,561 | $11,190 | $13,320 | $15,530 |